See more : Uscom Limited (UCM.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Arcellx, Inc. (ACLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcellx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Taihan Textile Co., Ltd. (001070.KS) Income Statement Analysis – Financial Results
- Firma Holdings Corp. (FRMA) Income Statement Analysis – Financial Results
- Kemp and Company Limited (KEMP.BO) Income Statement Analysis – Financial Results
- Kinarus Therapeutics Holding AG (PRFN.SW) Income Statement Analysis – Financial Results
- Grupo Mateus S.A. (GMAT3.SA) Income Statement Analysis – Financial Results
Arcellx, Inc. (ACLX)
About Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 110.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 2.22M | 1.04M | 629.00K | 326.00K | 0.00 |
| Gross Profit | 110.32M | -2.22M | -1.04M | -629.00K | -326.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 133.85M | 149.56M | 46.88M | 25.06M | 15.77M | 6.11M |
| General & Administrative | 66.35M | 41.70M | 18.14M | 7.04M | 2.21M | 2.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.35M | 41.70M | 18.14M | 7.04M | 2.21M | 2.20M |
| Other Expenses | 0.00 | 0.00 | 49.00K | 1.00K | 2.00K | 0.00 |
| Operating Expenses | 200.20M | 191.26M | 65.02M | 32.10M | 17.97M | 8.31M |
| Cost & Expenses | 200.20M | 191.26M | 65.02M | 32.10M | 17.97M | 8.31M |
| Interest Income | 23.70M | 4.30M | 300.00K | 1.00K | 0.00 | 0.00 |
| Interest Expense | 3.84M | 1.72M | 10.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.04M | 2.22M | 1.04M | 629.00K | 326.00K | 93.00K |
| EBITDA | -64.15M | -184.74M | -63.93M | -31.47M | -17.65M | -8.22M |
| EBITDA Ratio | -58.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -89.88M | -191.26M | -65.02M | -32.10M | -17.97M | -8.31M |
| Operating Income Ratio | -81.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.85M | 2.58M | 49.00K | 1.00K | 2.00K | 999.00 |
| Income Before Tax | -70.03M | -188.68M | -64.97M | -32.10M | -17.97M | -8.31M |
| Income Before Tax Ratio | -63.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 663.00K | -2.58M | -1.04M | 422.70K | 154.14K | 0.00 |
| Net Income | -70.69M | -186.10M | -63.93M | -32.10M | -17.97M | -8.31M |
| Net Income Ratio | -64.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.47 | -4.22 | -1.79 | -0.96 | -0.52 | -50.17 |
| EPS Diluted | -1.47 | -4.22 | -1.79 | -0.96 | -0.52 | -50.17 |
| Weighted Avg Shares Out | 48.06M | 44.11M | 35.74M | 33.54M | 34.78M | 165.58K |
| Weighted Avg Shares Out (Dil) | 48.06M | 44.11M | 35.74M | 33.54M | 34.78M | 165.58K |
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market
7 Biotech Stocks to Put on Your Breakthrough Radar
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports